Evidence map›Paper›PMID 37074429›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018.

Irene N Kasumba, Helen Powell, Richard Omore, M Jahangir Hossain, Samba O Sow, John Benjamin Ochieng, Henry Badji, Jennifer R Verani, Marc-Alain Widdowson, Sunil Sen and 21 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 5 countries.

Irene N KasumbaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Helen PowellCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Richard OmoreCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
M Jahangir HossainMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Samba O SowCentre pour le Developpement des Vaccins (CVD-Mali), Bamako, Mali.
John Benjamin OchiengCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Henry BadjiMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Jennifer R VeraniDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Marc-Alain WiddowsonDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Sunil SenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Shamima NasrinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jasnehta Permala-BoothCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jennifer A JonesCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Anna RooseCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dilruba NasrinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ciara E SugermanDivision of Foodborne, Waterborne, and Environmental Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jane JumaCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Alex AwuorCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Joquina Chiquita M JonesMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Sanogo DohCentre pour le Developpement des Vaccins (CVD-Mali), Bamako, Mali.
Catherine OkoiMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Syed M A ZamanMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Martin AntonioMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Elizabeth HunspergerDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Clayton OnyangoDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
James Platts-MillsDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Jie LiuDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Eric HouptDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · USMRC Unit the Gambia · GMCenters for Disease Control and Prevention · KEKenya Medical Research Institute · KECentre Pour le Développement des Vaccins-Mali · MLUniversity of Virginia · USCenters for Disease Control and Prevention · USQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.

methodsWe determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.

resultsBy qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.

conclusionsUnderstanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.

Indexed as

Anti-Infective AgentsTyphoid FeverVaccinesAnti-Bacterial AgentsChildChild, PreschoolDiarrheaHumansInfantInfant, NewbornMaliPrevalenceSalmonella enteritidisSalmonella typhimuriumSerogroupAnti-Bacterial AgentsAnti-Infective AgentsVaccinesAfricaantibiotic resistancechildrendiarrheaSalmonella

Identifiers

PMID37074429
PMCPMC10116559
OpenAlexW4366351277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.